Safety of antitumour necrosis factor-α therapy in psoriatic patients with hepatitis B virus infection

British Journal of Dermatology

Volumn 162, Issue 6, 2010, Pages 1408-1410

  Nosotti, L ^a   Francesconi, F ^b   Izzi, S ^b   Berardesca, E ^b   Morrone, A ^a   Bonifati, C ^b  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

Author keywords

Antitumour necrosis factor therapy; Hepatitis B virus; Inactive hepatitis B virus carrier; Occult hepatitis B virus carrier; Psoriasis

Indexed keywords

ADALIMUMAB; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ETANERCEPT; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIGEN DETECTION; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; COMORBIDITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEPATITIS B; HUMAN; LETTER; MALE; PRIORITY JOURNAL; PSORIASIS VULGARIS; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; VIRUS REACTIVATION;

ADULT; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA; VIRUS ACTIVATION;

EID: 77952719672     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.09714.x     Document Type: Letter

References (10)

1. Domm S, Cinatl J, Mrowietz U. The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: A review of the literature. Br J Dermatol 2008 159 : 1217 1228.
2. Carrol MB, Bond MI. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum 2008 38 : 208 217.
3. Chung SJ, Kim JA, Park MC et al. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy. J Rheumatol 2009 36 : 2416 2420.
4. Montiel PM, Solis JA, Chirinos A et al. Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. Liver Int 2008 28 : 718 720.
5. Conde-Taboada A, Muñoz JP, Muñoz LC, López-Bran E. Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection. J Am Acad Dermatol 2009 60 : 1077 1080.
6. Marzano A, Angelucci E, Androne P et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 2007 39 : 397 408.
7. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009 50 : 227 242.
8. Targhetta C, Cabras MG, Angelucci E. Risk of HBV liver disease in isolated antiHbc patients receiving immuno-chemotherapy for non Hodgkin lymphoma. Haematologica 2008 93 : e66.
9. Lok AS, McMahon BJ. Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations. Hepatology 2009 50 : 857 861.
10. Nathan DM, Angus PW, Gibson PR. Hepatitis B and C infections and anti-tumor necrosis factor-alpha: guidelines for clinical approach. J Gastroenterol Hepatol 2006 21 : 1366 1371.